Nash Videos

Prof. F. Tacke

Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany

As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.

View More ⏩Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany
Dr. Byrne

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2

It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.

View More ⏩Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2
Prof. Kenneth Cusi

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.

View More ⏩Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Prof. Sven Francque

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.

View More ⏩Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)